Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Purchases 5,000 Shares of Stock

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) CEO Seth Lederman bought 5,000 shares of Tonix Pharmaceuticals stock in a transaction dated Tuesday, June 9th. The shares were bought at an average cost of $11.79 per share, for a total transaction of $58,950.00. Following the completion of the acquisition, the chief executive officer owned 9,005 shares in the company, valued at $106,168.95. This represents a 124.84% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Seth Lederman also recently made the following trade(s):

• On Wednesday, March 18th, Seth Lederman bought 15,000 shares of Tonix Pharmaceuticals stock. The shares were bought at an average cost of $14.89 per share, for a total transaction of $223,350.00.

Tonix Pharmaceuticals Stock Performance

TNXP opened at $11.46 on Wednesday. The firm has a market cap of $182.67 million, a P/E ratio of -0.80 and a beta of 1.67. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $10.87 and a 52-week high of $69.97. The business’s fifty day moving average is $13.17 and its 200-day moving average is $15.03.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its earnings results on Monday, May 11th. The company reported ($2.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.54) by ($0.39). The company had revenue of $6.88 million for the quarter, compared to analyst estimates of $6.13 million. Tonix Pharmaceuticals had a negative return on equity of 67.65% and a negative net margin of 839.52%. On average, research analysts predict that Tonix Pharmaceuticals Holding Corp. will post -9.94 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

Several large investors have recently bought and sold shares of TNXP. Vanguard Group Inc. boosted its stake in Tonix Pharmaceuticals by 238.1% in the third quarter. Vanguard Group Inc. now owns 556,957 shares of the company’s stock valued at $13,456,000 after buying an additional 392,225 shares in the last quarter. Balyasny Asset Management L.P. acquired a new stake in Tonix Pharmaceuticals in the fourth quarter valued at about $2,895,000. Geode Capital Management LLC boosted its stake in Tonix Pharmaceuticals by 182.4% in the second quarter. Geode Capital Management LLC now owns 175,212 shares of the company’s stock valued at $6,305,000 after buying an additional 113,175 shares in the last quarter. Nuveen LLC boosted its stake in shares of Tonix Pharmaceuticals by 507.7% during the fourth quarter. Nuveen LLC now owns 93,402 shares of the company’s stock valued at $1,459,000 after purchasing an additional 78,033 shares in the last quarter. Finally, Capital Fund Management S.A. acquired a new stake in shares of Tonix Pharmaceuticals during the third quarter valued at about $1,521,000. 82.26% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Tonix Pharmaceuticals in a report on Monday, April 20th. Wall Street Zen lowered Tonix Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, April 26th. Finally, TD Cowen raised Tonix Pharmaceuticals to a “strong-buy” rating in a research note on Tuesday, May 5th. One research analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Tonix Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $22.00.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals is a clinical-stage biotechnology company focused on developing therapeutics for central nervous system disorders, immunology and rare diseases. The company’s pipeline includes small-molecule and biologic product candidates designed to address conditions such as fibromyalgia, post-traumatic stress disorder (PTSD) and other chronic pain syndromes, as well as vaccines for potential viral and biothreat agents.

Among Tonix’s lead programs is TNX-102 SL, a sublingual formulation of cyclobenzaprine being evaluated for the treatment of fibromyalgia and PTSD.